Lugo

• LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib in RET fusion-Positive NSCLC Recruiting
  2023-506784-33-00 5 2021-01-19 RET fusion-Positive NSCLC
• A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney D … Recruiting
  2025-523123-22-00 5 2026-05-07 Chronic Kidney Disease
• A study to compare Venetoclax Azacitidine and Quizartinib Vs Venetoclax and Azacitidine in newly diagnosed acute myeloid leukemia patient´s … Recruiting
  2025-522979-29-00 5 2026-04-30 Acute myeloid leukemia
• HF-POLARIS: A research study to look at how well NNC0487-0111 works compared to placebo in people with heart failure and obesity Recruiting
  2025-523717-29-00 5 2026-04-28 HFpEF or HFmrEF and obesity
• ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting
  2025-522960-34-00 5 2026-02-09 Established cardiovascular disease
• Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Pembrolizumab with Platinum-based Chemotherapy in First-line HER2 o … Recruiting
  2024-515658-26-00 5 2026-01-21 Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-
• Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Subjects With Primary Membranous Nephropathy Recruiting
  2025-521661-27-00 10 2025-12-19 Primary Membranous Nephropathy
• Atacicept in Multiple Glomerular Diseases Recruiting
  2024-518465-10-00 4 2025-12-12 Multiple Autoimmune Glomerular Diseases
• Phase II study of tarlatamab as a follow-up treatment after chemo and radiation in patients with small cell lung cancer (SCLC) who cannot re … Recruiting
  2024-515201-26-00 4 2025-12-09 Small cell lung cancer (SCLC)
• Evaluation of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF) Recruiting
  2025-521278-32-00 4 2025-12-04 Idiopathic Pulmonary Fibrosis (IPF)
• A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis Recruiting
  2025-521242-26-00 4 2025-11-27 Moderately to Severely Active Ulcerative Colitis
• Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Recruiting
  2025-520555-89-00 5 2025-11-14 Metastatic castration-resistant prostate cancer (mCRPC)
• A phase 2 placebo-controlled trial to investigate visugromab and nivolumab with or without docetaxel in second-line treatment of participant … Recruiting
  2024-516794-70-00 4 2025-11-03 Metastatic non-squamous non-small cell lung cancer
• An open-label study of JSB462 (luxdegalutamide) in combination with abiraterone in adult male patients with metastatic hormone-sensitive pro … Recruiting
  2024-520156-22-00 4 2025-10-08 Metastatic hormone-sensitive prostate cancer
• A Phase 3 study of NBTXR3 with or without cetuximab in LA-HNSCC Recruiting
  2024-520386-31-00 5 2025-09-22 Locally Advanced Head & Neck Squamous Cell Carcinoma
• A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-line Treatment of PD-L1-high Metastatic Non-small Cell Lung … Recruiting
  2024-517780-24-00 5 2025-09-18 Lung Cancer
• SAKK 08/23: Addition of Darolutamide to first line treatment of mCRPC: a randomized open label phase II trial Recruiting
  2024-512132-29-00 4 2025-08-06 Metastatic castration-resistant prostate cancer
• Phase 3 Study of I-DXd Versus Docetaxel in mCRPC Recruiting
  2024-517423-40-00 5 2025-06-23 Metastatic Castration-Resistant Prostate Cancer
• Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction Recruiting
  2024-519219-32-00 5 2025-06-23 Heart Failure With Reduced Ejection Fraction
• EORTC-2238-GUCG: Improving impact of anti-androgen treatments on patient's daily life and their cancer Recruiting
  2023-506817-23-01 5 2025-05-23 Metastatic hormone naïve prostate cancer (mHNPC)
• A Phase 3 Study Comparing BMS-986365 versus Investigator’s Choice of Therapy in Participants with Metastatic Castration-resistant Prostate C … Recruiting
  2024-517422-25-00 5 2025-05-22 Metastatic Castration-resistant Prostate Cancer (mCRPC)
• Cetuximab With or Without Paclitaxel After Pembrolizumab-Chemotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck. Recruiting
  2024-514953-31-00 4 2025-05-20 Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
• Phase II clinical trial of chemotherapy + atezolizumab for stage IIIa and IIIb non-small cell lung cancer followed by atezolizumab as adjuva … Recruiting
  2024-515984-68-00 4 2025-05-20 Non-small cell lung cancer (NSCLC)
• A trial to learn how well benralizumab works and how safe it is when given in addition to standard asthma treatments in people with eosinoph … Recruiting
  2024-515162-13-00 5 2025-04-29 Eosinophilic Asthma

Showing 25–48 of 136 trials